Pre-apheresis T-cell fitness in chimeric antigen receptor T-cell therapy.
The quality of immune cells collected before manufacturing CAR-T therapy predicts manufacturing success, pointing toward better pre-screening to reduce failed manufacturing attempts.
Review from Tongji Hospital synthesizes evidence that the biological quality of leukapheresis starting material is as important as T-cell quantity in determining CAR-T manufacturing outcomes and clinical efficacy. Identifying a 'favorable pre-collection window' and standardizing pre-apheresis T-cell fitness assessment could improve manufacturing success rates and reduce manufacturing failures, a key clinical bottleneck.
What the study was
- Study design
- Narrative review
- Category
- Novel therapeutics: immunotherapy, CAR-T, targeted therapy
- Maturity
- Exploratory
- Journal
- Transl Oncol
Why it surfaced
Timely review addressing a critical operational gap in CAR-T therapy (manufacturing failures due to poor starting material); Tongji/Huazhong University; published in Translational Oncology; directly actionable for CAR-T program design. Complements 43033914 (real-world CAR-T access data).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.